New antibody drug shows promise for blocking asthma attacks
NCT ID NCT00983658
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This phase II trial tested a drug called huMAb OX40L in 29 adults with mild allergic asthma. The drug is an antibody designed to block a protein that triggers allergic reactions in the airways. Researchers measured whether it could prevent breathing problems caused by allergens, compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
huMAb OX40L (a lab-made antibody that blocks a protein involved in allergic reactions)
What this could lead to
If it works, this could point toward a new treatment to control asthma attacks triggered by allergens.
What could go wrong
This is a small, early-phase trial with only 29 people. The drug may not work better than placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.